Ryo Hatano - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ryo Hatano

Showing results (81-90 of 83) with videos related to

Pageof 9

Sort By:

You have reached the last page of results.This site can display upto 83 results.

Biomarker Research|March 24, 2021

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibodyYutaro Kaneko, Ryo Hatano, Naoto Hirota, et al.

Scientific Reports|December 30, 2025

Novel anti-ITGA4 monoclonal antibody induces cell death via large pore formation in NK/T-cell lymphoma cellsShiori Takeuchi, Yasuhiko Ito, Shuji Matsuoka, et al.

Cells|April 13, 2023

DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological MalignanciesShohei Kikuchi, Akinori Wada, Yusuke Kamihara, et al.

Pageof 9

Search research articles

Showing results (81-90 of 83) with videos related to

Sort By:

Pageof 9

You have reached the last page of results.This site can display upto 83 results.

Biomarker Research|March 24, 2021

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibodyYutaro Kaneko, Ryo Hatano, Naoto Hirota, et al.

Scientific Reports|December 30, 2025

Novel anti-ITGA4 monoclonal antibody induces cell death via large pore formation in NK/T-cell lymphoma cellsShiori Takeuchi, Yasuhiko Ito, Shuji Matsuoka, et al.

Cells|April 13, 2023

DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological MalignanciesShohei Kikuchi, Akinori Wada, Yusuke Kamihara, et al.

Pageof 9